Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Timing of birth and risk of multiple sclerosis: population based study.
Interferon-beta1b for the treatment of multiple sclerosis.
Neurorehabilitation Topics in Patients with Multiple Sclerosis: From Outcome Measurements to Rehabilitation Interventions.
The pathogenesis of demyelinating form of Guillain-Barre syndrome: proteo-peptidomic and immunological profiling of physiological fluids.
Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.
Predictors and dynamics of postpartum relapses in women with multiple sclerosis.
Intrathecal interferon reduces exacerbations of multiple sclerosis.
Policy: NIH to balance sex in cell and animal studies.
Association of common mitochondrial DNA variants with multiple sclerosis and systemic lupus erythematosus.
Hematopoietic stem cell transplantation for MS: extraordinary evidence still needed.
The "poison chair" treatment for multiple sclerosis.
Glial cells as drug targets: What does it take?
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.
EMD Serono and Pfizer announce FDA approval of Rebif® Rebidose® (interferon beta-1a)
Recent insights into the mechanism of action of glatiramer acetate.
Association Between Sleep Problems and Perceived Cognitive Dysfunction Over 12 Months in Individuals with Multiple Sclerosis.
Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis.
Neurons and astroglia govern microglial endotoxin tolerance through macrophage colony-stimulating factor receptor-mediated ERK1/2 signals.
Autoimmune myelopathies.
Immunopathology: autoimmune glial diseases and differentiation from multiple sclerosis.
Multiple sclerosis: Could Helicobacter pylori provide protection against multiple sclerosis?
Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing-remitting multiple sclerosis.
Rituximab for relapsing-remitting multiple sclerosis.
Understanding the Role of T Cells in CNS Homeostasis.
Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein.
Pages
« first
‹ previous
…
73
74
75
76
77
78
79
80
81
…
next ›
last »